Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.46 |
| ▸ | GRM5 | P41594 | 10/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206105 | 0.88 | NAMPT (0.40) | NAMPTPDK4GRM1GRM5ACKR3 | |
| SCHEMBL2831127 | 0.83 | NAMPT (0.59) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL24669280 | 0.83 | NAMPT (0.62) | NAMPTPDK4GRM1GRM5ACKR3 | |
| SCHEMBL24667826 | 0.81 | NAMPT (0.49) | NAMPTPDK4GRM1GRM5JAK1 | |
| SCHEMBL29803404 | 0.81 | NAMPT (0.49) | NAMPTPDK4GRM1GRM5JAK1 | |
| SCHEMBL29803366 | 0.81 | WDR5 (0.49) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL24670346 | 0.81 | NAMPT (0.48) | NAMPTPDK4GRM1GRM5ACKR3 | |
| SCHEMBL24671087 | 0.80 | PDK4 (0.50) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL31283668 | 0.80 | PDK4 (0.52) | NAMPTPDK4GRM1GRM5HTR6 | |
| SCHEMBL1061832 | 0.80 | PDK4 (0.52) | NAMPTPDK4GRM1GRM5HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501508-B1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| US-20050222410-A1 | Inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1501508-A1 | INHIBITORS OF HISTONE DEACETYLASE | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003092686-A1 | INHIBITORS OF HISTONE DEACETYLASE | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222410-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | NAMPT 776/4885PDK4 829/4885GRM1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.